{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:42:14Z","timestamp":1793900534801,"version":"4.8.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced fibrosis caused by nonalcoholic steatohepatitis (NASH). We analyzed screening data from two phase 3 trials of selonsertib to assess the ability of NITs to discriminate advanced fibrosis. Centrally read biopsies from the STELLAR studies, which enrolled patients with bridging fibrosis and compensated cirrhosis, were staged according to the NASH Clinical Research Network classification. We explored associations between fibrosis stage and NITs, including the nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis\u20104 (FIB\u20104) index, Enhanced Liver Fibrosis (ELF) test, and liver stiffness by vibration\u2010controlled transient elastography (LS by VCTE). The performance of these tests to discriminate advanced fibrosis, either alone or in combinations, was evaluated using areas under the receiver operating characteristic curve (AUROCs) with 5\u2010fold cross\u2010validation repeated 100 times. Of the 4,404 patients screened for these trials, 3,202 had evaluable biopsy data: 940 with F0\u2010F2 fibrosis and 2,262 with F3\u2010F4 fibrosis. Significant differences between median values of NITs for patients with F0\u2010F2 versus F3\u2010F4 fibrosis were observed: \u22120.972 versus 0.318 for NFS, 1.18 versus 2.20 for FIB\u20104, 9.22 versus 10.39 for ELF, and 8.8 versus 16.5 kPa for LS by VCTE (all <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001). AUROCs ranged from 0.75 to 0.80 to discriminate advanced fibrosis. FIB\u20104 followed by an LS by VCTE or ELF test in those with indeterminate values (FIB\u20104 between 1.3 and 2.67) maintained an acceptable performance while reducing the rate of indeterminate results. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Among patients being considered for enrollment into clinical trials, NITs alone or in combination can reduce the need for liver biopsy to discriminate advanced fibrosis caused by NASH. The predictive value of these tests for general screening will require confirmation in a real\u2010world population.<\/jats:p>","DOI":"10.1002\/hep.30842","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T18:43:35Z","timestamp":1562265815000},"page":"1521-1530","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":270,"title":["Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials"],"prefix":"10.1097","volume":"70","author":[{"given":"Quentin M.","family":"Anstee","sequence":"first","affiliation":[{"name":"Institute of Cellular Medicine, Faculty of Medical Sciences,Newcastle University,Newcastle upon Tyne,United Kingdom"},{"name":"The Liver Unit,Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust,Newcastle upon Tyne,United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Texas Liver Institute,University of Texas Health San Antonio,San Antonio,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9872-2391","authenticated-orcid":false,"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[{"name":"Texas Liver Institute,University of Texas Health San Antonio,San Antonio,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-9410","authenticated-orcid":false,"given":"Vincent Wai\u2010Sun","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics,The Chinese Hospital of Hong Kong,Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero\u2010Gomez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Rocio,Seville,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[{"name":"Saiseikai Suita Hospital,Suita City, Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Kersey","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Li","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Han","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Jia","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Djedjos","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kohli","sequence":"additional","affiliation":[{"name":"The Institute for Liver Health,Chandler,AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bzowej","sequence":"additional","affiliation":[{"name":"Ochsner Medical Center,New Orleans,LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Younes","sequence":"additional","affiliation":[{"name":"Gastro One,Germantown,TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0544-5610","authenticated-orcid":false,"given":"Shiv","family":"Sarin","sequence":"additional","affiliation":[{"name":"Institute of Liver and Biliary Sciences,New Delhi,Delhi,India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[{"name":"Bon Secours Liver Institute of Virginia,Richmond,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Pinnacle Clinical Research,San Antonio,TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam H.","family":"Afdhal","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center and Harvard Medical School,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[{"name":"Inova Fairfax Hospital,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[{"name":"Inova Fairfax Hospital,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"hep30842-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep30842-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep30842-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30842-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"hep30842-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease\u2010specific mortality in NAFLD after up to 33 years of follow\u2010up","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep30842-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long\u2010term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30842-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep30842-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30842-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator\u2010activated receptor\u2010\u03b1 and \u2010\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30842-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non\u2010cirrhotic, non\u2010alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo\u2010controlled trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep30842-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30842-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep30842-bib-0013-20241017","first-page":"328","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2017","journal-title":"Hepatology"},{"key":"hep30842-bib-0014-20241017","first-page":"1017","article-title":"American Association for the Study of Liver Diseases. Liver biopsy","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep30842-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","year":"2005","journal-title":"Gastroenterology"},{"key":"hep30842-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"hep30842-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30842-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep30842-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut\u2010off values","volume":"59","year":"2013","journal-title":"J Hepatol"},{"key":"hep30842-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ajg.2016.49","article-title":"The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"hep30842-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1016\/S0168-8278(17)31608-2","article-title":"Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep30842-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non\u2010invasive diagnosis of advanced NAFLD fibrosis","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"hep30842-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jhep.2008.07.039","article-title":"Exceeding the limits of liver histology markers","volume":"50","year":"2009","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"hep30842-bib-0024-20241017","first-page":"67","article-title":"Diagnosis of non\u2010alcoholic fatty liver disease\/non\u2010alcoholic steatohepatitis: non\u2010invasive tests are enough","volume":"38","year":"2018","journal-title":"Liver Int"},{"issue":"Suppl","key":"hep30842-bib-0025-20241017","first-page":"44A","article-title":"Impact of pre\u2010screening with Fibrosis\u20104 index on a referral pathway for patients with suspected NAFLD","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep30842-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2468-1253(18)30077-3","article-title":"Non\u2010alcoholic fatty liver disease and the interface between primary and secondary care","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep30842-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non\u2010alcoholic fatty liver disease","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep30842-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/hepr.13226","article-title":"Accuracy of non\u2010invasive scoring systems for diagnosing non\u2010alcoholic steatohepatitis\u2010related fibrosis: multicenter validation study","volume":"48","year":"2018","journal-title":"Hepatol Res"},{"key":"hep30842-bib-0029-20241017","article-title":"Validation of serum test for advanced liver fibrosis in patients with nonalcoholic steatohepatitis","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30842-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hep.28226","article-title":"Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep30842-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00535-017-1355-9","article-title":"A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis","volume":"53","year":"2018","journal-title":"J Gastroenterol"},{"key":"hep30842-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta\u2010analysis","volume":"66","year":"2017","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:38:32Z","timestamp":1729211912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30842","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"2018-12-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}